| Autor: |
Olukosi AY; Nigerian Institute of Medical Research, Lagos, Nigeria.; EKO University of Medical and Health Sciences, Lagos, Nigeria., Musa AZ; Nigerian Institute of Medical Research, Lagos, Nigeria., Ogbulafor N; National Malaria Elimination Program, Abuja, Nigeria., Aina O; Nigerian Institute of Medical Research, Lagos, Nigeria., Mokuolu O; University of Ilorin, Kwara, Nigeria., Oguche S; University of Jos, Plateau, Nigeria., Wammanda R; Ahmadu Bello University, Zaria, Nigeria., Okafor H; University of Nigeria Teaching Hospital, Enugu, Nigeria., Ekama SO; Nigerian Institute of Medical Research, Lagos, Nigeria., David AN; Nigerian Institute of Medical Research, Lagos, Nigeria., Happi CT; Redeemer's University Ede, Osun, Nigeria., Ozor L; WHO, Abuja, Nigeria., Babatunde S; WHO, Abuja, Nigeria., Ijezie SN; National Malaria Elimination Program, Abuja, Nigeria., Uhomoibhi PE; National Malaria Elimination Program, Abuja, Nigeria., Awolola ST; Nigerian Institute of Medical Research, Lagos, Nigeria., Mohammed AB; National Malaria Elimination Program, Abuja, Nigeria., Salako BL; Nigerian Institute of Medical Research, Lagos, Nigeria. |
| Abstrakt: |
Prior to 2018, malaria therapeutic efficacy studies (TESs) in Nigeria were implemented separately at different sites, as assigned by the National Malaria Elimination Program (NMEP). In 2018, however, the NMEP engaged the Nigerian Institute of Medical Research to coordinate the 2018 TESs in 3 of 14 sentinel sites with the objective of standardizing their conduct across all three sites: Enugu, Kano, and Plateau states in three of six geopolitical zones. Artemether-lumefantrine and artesunate-amodiaquine, the two first-line drugs for treatment of acute uncomplicated malaria in Nigeria, were tested in both Kano and Plateau states. In Enugu State, however, artemether-lumefantrine and dihydroartemisinin-piperaquine were the test drugs, with dihydroartemisinin-piperaquine being tested for potential inclusion in Nigerian treatment policy. The TES was conducted in 6-month to 8-year-old children and was funded by the Global Fund with additional support from the WHO. A multipartite core team comprised of the NMEP, the WHO, the U.S. Presidential Malaria Initiative, academia, and the Nigerian Institute of Medical Research was set up to oversee the execution of the 2018 TES. This communication reports best practices adopted to guide its coordination, and lessons learned during in the process, including applying developed standard operating procedures, powering the sample size adequately for each site to report independently, training the investigating team for fieldwork, facilitating stratification of decisions, determining efficiencies derived from monitoring and quality assessment, and optimizing logistics. The planning and coordination of the 2018 TES activities is a model of a consultative process for the sustainability of antimalarial resistance surveillance in Nigeria. |
